Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.

Trial Profile

Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2011

At a glance

  • Drugs Bleomycin; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine; Vindesine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2011 Additional lead trial centre and investigators identified as reported by ClinicalTrials.gov.
    • 27 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top